Comparative Pharmacology
Head-to-head clinical analysis: FLOXIN versus PROQUIN XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLOXIN versus PROQUIN XR.
FLOXIN vs PROQUIN XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibition of bacterial DNA gyrase and topoisomerase IV, preventing DNA replication, transcription, repair, and recombination.
Fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription.
400 mg orally every 12 hours for 10-14 days; ophthalmic solution: 1-2 drops in affected eye(s) every 2-4 hours for 2 days, then 1-2 drops 4 times daily for 10 days; otic solution: 5-10 drops in affected ear(s) twice daily for 10-14 days.
500 mg orally once daily with food.
None Documented
None Documented
Terminal elimination half-life of 10-14 hours in patients with normal renal function; prolonged in renal impairment (up to 40-50 hours in severe cases).
Terminal elimination half-life is approximately 10-14 hours in patients with normal renal function (CrCl >80 mL/min). Extended half-life may occur in renal impairment, necessitating dose adjustment.
Approximately 70-90% excreted unchanged in urine via glomerular filtration and tubular secretion; about 10-30% eliminated in feces via biliary excretion.
Primarily renal excretion of unchanged drug (~60-80%) via glomerular filtration and tubular secretion. Biliary/fecal excretion accounts for approximately 20-35%, with a small portion as metabolites.
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic